Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

NCT00623727 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00623727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2008
Completion date
October 31, 2010
Enrollment
143 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a